Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study.

医学 中期分析 临床终点 内科学 化疗 安慰剂 肺癌 阶段(地层学) 围手术期 肿瘤科 外科 随机化 非小细胞肺癌 临床试验 病理 古生物学 替代医学 生物 A549电池
作者
Shun Lü,Lin Wu,Wei Zhang,Peng Zhang,Wenxiang Wang,Wentao Fang,Wenqun Xing,Qixun Chen,Jiandong Mei,Lin Yang,Lijie Tan,Xiaokang Sun,Shidong Xu,Xiaohua Hu,Guohua Yu,Dongliang Yu,Jinlu Shan,Nong Yang,Yuping Chen,Hui Tian
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (16_suppl): 8501-8501 被引量:15
标识
DOI:10.1200/jco.2023.41.16_suppl.8501
摘要

8501 Background: Adjuvant and neoadjuvant immunotherapy have been approved by US FDA to treat early-stage NSCLC. However, the optimal neoadjuvant and adjuvant treatment, including duration of treatment, are unknown. We present the interim results of a randomized, double-blind, placebo-controlled, Phase III trial to evaluate the efficacy and safety of perioperative toripalimab plus chemotherapy followed by toripalimab maintenance vs chemotherapy in resectable stage III NSCLC. Methods: Patients with stage II/III resectable NSCLC, without EGFR/ALK alterations for non-squamous NSCLC, were randomized 1:1 to receive 240 mg toripalimab or placebo combined with chemotherapy Q3W for 3 cycles before surgery and one cycle after surgery, followed by toripalimab or placebo monotherapy Q3W for 13 cycles. Stratification variables for randomization included disease stage, histopathologic subtype, PD-L1 expression and surgical procedure. Primary endpoints were EFS by investigator and major pathological response (MPR) rate by a blinded independent pathologic review (BIPR) in the stage III and the ITT populations. Secondary endpoints included overall survival (OS), pathologic complete response (pCR) rate, EFS by independent review committee (IRC), and safety. A planned interim analysis was performed on the primary endpoint of EFS in the stage III subjects. Results: A total of 404 stage III NSCLC patients were randomized to toripalimab (n=202) or placebo (n=202). By the data cutoff date (November 30, 2022), the median follow-up was 18.3 months. Baseline characteristics were well balanced between the two arms. EFS was significantly improved in the toripalimab arm, HR=0.40, 95% CI (0.277-0.565), P<0.0001, and crossed the pre-specified efficacy boundary. The median EFS was not reached in the toripalimab arm and 15.1 months in the placebo arm. A consistent effect on EFS, favoring toripalimab, was observed in all subgroups. The MPR and pCR rates per BIPR were also higher in the toripalimab arm, 48.5% vs 8.4% and 24.8% vs 1.0%, respectively. The OS results showed a trend favoring toripalimab. The incidence of Grade ≥3 adverse events (AEs) (63.4% vs 54.0%), fatal AEs related to toripalimab/placebo (0.5% vs 0%) and AEs leading to discontinuation of toripalimab/placebo (9.4% vs 7.4%) were comparable between the two arms. However, the incidence of immune-related AEs (42.1% vs 22.8%) was more frequent in the toripalimab arm. Conclusions: The addition of toripalimab to perioperative chemotherapy showed statistically significant improvements in EFS for stage III NSCLC patients with a manageable safety profile. Patients will be followed for overall survival. Clinical trial information: NCT04158440 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ran发布了新的文献求助10
刚刚
...发布了新的文献求助10
1秒前
2秒前
春秋完成签到,获得积分10
2秒前
ltt发布了新的文献求助10
3秒前
火星上莛发布了新的文献求助10
3秒前
核桃发布了新的文献求助10
4秒前
666pop发布了新的文献求助10
4秒前
小蘑菇应助二艺采纳,获得10
6秒前
岁月轮回发布了新的文献求助10
6秒前
6秒前
7秒前
科研通AI5应助ltt采纳,获得10
7秒前
8秒前
上官若男应助cc采纳,获得10
9秒前
9秒前
星际牛仔完成签到,获得积分10
10秒前
10秒前
澡雪发布了新的文献求助10
10秒前
pojian发布了新的文献求助10
12秒前
朴实觅波完成签到,获得积分10
12秒前
岁月轮回完成签到,获得积分10
13秒前
柯一一应助你好啊采纳,获得10
13秒前
无忧诀发布了新的文献求助10
13秒前
13秒前
14秒前
FashionBoy应助耶瑟儿采纳,获得30
14秒前
tjzbw完成签到,获得积分10
14秒前
搜集达人应助666pop采纳,获得10
16秒前
xdm发布了新的文献求助30
16秒前
17秒前
18秒前
frank19776发布了新的文献求助10
19秒前
19秒前
华仔应助糊涂的猎豹采纳,获得10
22秒前
风趣安青发布了新的文献求助10
25秒前
25秒前
916应助湛湛采纳,获得10
26秒前
xyzdmmm发布了新的文献求助200
27秒前
量子星尘发布了新的文献求助10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975693
求助须知:如何正确求助?哪些是违规求助? 3520019
关于积分的说明 11200635
捐赠科研通 3256410
什么是DOI,文献DOI怎么找? 1798255
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390